Finasteride Monitoring for Older Adults (50 to 64): Lab Tests, PSA Adjustments, and Safety Checks

What does finasteride do to PSA?

Finasteride lowers PSA. The Proscar (5 mg) label states that PSA falls by approximately 50% within six months of treatment, that the decrease is predictable across the whole PSA range in men with symptomatic BPH, and that it can still vary between individuals [1].

At 1 mg, the Propecia label reports mean PSA falling from 0.7 to 0.5 ng/mL at month 12 in men aged 18 to 41, the group the hair-loss program studied [2]. The Proscar label says percent free PSA remains constant, with no adjustment to it appearing necessary, and notes that non-compliance with therapy may affect PSA results [1].

The trials behind these labels overlap the 50-to-64 age band unevenly: the 5 mg BPH safety study enrolled men aged 45 to 78, and the Prostate Cancer Prevention Trial enrolled men 55 and older [1]. Neither label gives a separate PSA rule for men aged 50 to 64 [2][1].

How do you read a PSA in a man taking finasteride?

The Proscar label is specific. A new PSA baseline should be established at least six months after starting treatment, PSA should be monitored periodically after that, and any confirmed increase from the lowest value on treatment may signal prostate cancer and should be evaluated even if the number is still within the normal range for men not taking a 5-alpha reductase inhibitor [1]. To interpret an isolated value in someone who has taken Proscar for six months or more, the label says to double it for comparison with normal ranges in untreated men [1].

Longer follow-up changes the arithmetic a little. In an analysis of Prostate Cancer Prevention Trial data, the factor needed to preserve median PSA rose from 2 at 24 months to 2.5 at seven years after starting finasteride [3]. The same analysis found PSA rising about 15% per year in the years before an interim cancer diagnosis among men on finasteride, versus 11% on placebo, and falling about 2% per year in men on finasteride with no cancer at the end-of-study biopsy [3].

The Propecia label handles this differently. It states the same warning — any confirmed increase from the lowest PSA value while on treatment should be evaluated even if the value is still normal for untreated men — but the doubling instruction appears in the 5 mg label, not in the 1 mg one [2][1].

What safety checks do the labels actually specify?

The labels' monitoring language is about PSA. The warnings sections of both the Propecia and Proscar labels cover PSA interpretation, the high-grade prostate cancer finding, fetal risk, and the fact that finasteride is not indicated for women or children, and neither sets out a liver function, lipid, glucose, hormone or blood-count monitoring schedule [2][1]. The Proscar label adds that men with a large residual urinary volume or severely diminished urinary flow should be carefully monitored for obstructive uropathy, and that caution should be exercised in patients with liver function abnormalities [1].

Finasteride is extensively metabolized in the liver, mainly by CYP3A4, with a mean terminal half-life of about 5 to 6 hours in men aged 18 to 60 and about 8 hours in men over 70; because the enzyme complex it blocks turns over slowly, roughly every 30 days, the effect on DHT outlasts the plasma half-life [2].

On interactions, both labels report that no drug interactions of clinical importance have been identified and that finasteride does not appear to affect the cytochrome P450 system; compounds tested in humans include antipyrine, digoxin, propranolol, theophylline and warfarin, with no clinically meaningful interactions [2][1]. The labels add that in clinical studies finasteride was used alongside ACE inhibitors, alpha-blockers, beta blockers, calcium channel blockers, diuretics, statins, NSAIDs, benzodiazepines and quinolone antibiotics without evidence of clinically significant adverse interactions, although specific interaction studies were not run for those pairings [1].

One combination is a labeled indication rather than a caution: Proscar with the alpha-blocker doxazosin is approved to reduce the risk of symptomatic BPH progression [1]. The Medical Therapy of Prostatic Symptoms trial, which enrolled 3,047 men over a mean 4.5 years, found a 34% reduction in overall clinical progression with finasteride alone versus placebo and a 66% reduction with combination therapy [4].

Sexual side effects: what the trials measured

In three 12-month Propecia trials in 945 men on finasteride and 934 on placebo, 3.8% of treated men reported one or more sexual adverse experiences versus 2.1% on placebo (p=0.04), and the incidence of each fell to 0.3% or lower by year five [2]. In the 5 mg PLESS study of 1,524 men on finasteride and 1,516 on placebo, year-one rates were impotence 8.1% versus 3.7%, decreased libido 6.4% versus 3.4%, decreased ejaculate volume 3.7% versus 0.8%, and ejaculation disorder 0.8% versus 0.1%; in years two to four there was no significant difference between groups for impotence, libido or ejaculation disorder [1]. Discontinuation for sexual adverse reactions was 3.7% on finasteride versus 2.1% on placebo [1].

A meta-analysis of 15 randomized placebo-controlled trials covering 4,495 men treated for androgenetic alopecia with finasteride 1 mg or dutasteride 0.5 mg found a relative risk of sexual dysfunction of 1.57 (95% CI 1.19 to 2.08) overall and 1.66 (1.20 to 2.30) for finasteride [5]. How well those events were captured is contested: a review of 34 finasteride trials for hair loss found none with adequate safety reporting, most evaluating safety for a year or less, with patterns suggesting under-detection of sexual adverse effects [6].

Are mood and suicide risks established in this age group?

The current Propecia label lists depression, suicidal ideation and behavior, and the current Proscar label lists depression and suicidal ideation, among postmarketing reports; the labels state that these reports are voluntary, come from a population of uncertain size, and cannot reliably establish cause [2][1]. They are not boxed warnings [2][1].

Two large cohorts have looked at this in older men. In Ontario, 93,197 men aged 66 or older starting a 5-alpha reductase inhibitor were compared with matched untreated men: suicide hazard ratio 0.88 (95% CI 0.53 to 1.45), self-harm hazard ratio 1.88 (1.34 to 2.64) in the first 18 months only, and depression hazard ratio 1.94 (1.73 to 2.16) in the first 18 months and 1.22 (1.08 to 1.37) afterward, with absolute increases of 17 self-harm and 237 depression cases per 100,000 patient-years [8]. In Sweden, 2,236,876 men aged 50 to 90 were followed, 70,645 of whom started finasteride: depression hazard ratio 1.61 (1.48 to 1.75), constant over time, and no clear suicide association (hazard ratio 1.22, 0.99 to 1.49) [9]. Both cohorts were mostly older men treated for prostate symptoms (Ontario: aged 66 or older; Swedish finasteride starters: median age 73), so they say little about men aged 50 to 64 taking 1 mg for hair loss [8][9].

What changes if the prescription is the 1 mg hair-loss dose?

Propecia is indicated for male pattern hair loss in men only, is not indicated for women, and has not established efficacy in bitemporal recession [2]. The dose is one 1 mg tablet daily, with or without food; daily use for three months or more is usually needed before benefit appears, continued use is needed to sustain it, and withdrawal leads to reversal of effect within 12 months [2]. The trials behind approval enrolled men aged 18 to 41, so the hair-count data do not describe a man in his 50s or 60s [2][10]. In those trials, hair count in a 1-inch circle of vertex scalp rose 107 hairs above placebo at one year and 138 above placebo at two years (P<0.001) [10].

Two label points apply regardless of age: women who are or may be pregnant must not take finasteride or handle crushed or broken tablets, and intact coated tablets prevent that contact [2]. HealthRX.com offers finasteride 1 mg by prescription.

What does the high-grade prostate cancer finding mean after 55?

In the Prostate Cancer Prevention Trial, 18,882 men aged 55 or older with a normal digital rectal exam and PSA of 3.0 ng/mL or less took finasteride 5 mg or placebo for seven years; Gleason 8 to 10 cancer was found in 1.8% of men on finasteride versus 1.1% on placebo [1]. Overall prostate cancer was detected in 18.4% of evaluable men on finasteride versus 24.4% on placebo, a 24.8% relative reduction (95% CI 18.6 to 30.6) [11]. The labels state that 5-alpha reductase inhibitors may increase the risk of high-grade prostate cancer, that whether reduced prostate volume or study-related factors affected the result has not been established, and that Proscar is not approved to prevent prostate cancer [1].